Firategrast
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Firategrast是口服有效的整合素α4β1/α4β7小分子拮抗剂[1]。
整合素是一类跨膜受体,可以调节从细胞外基质到细胞内的信号转导。整合素与许多疾病相关,如癌症、炎症和血栓性疾病。由于整合素部分暴露于细胞外,易于与药物结合,因而被认为是攻击的靶点。现已开发和合成了多种靶向整合素的药物,如Abciximab、 Tirofiban、Lamifiban和Natalizumab。在上述药物中,Firategrast被研发用于治疗由白细胞(如单核细胞、T细胞、B细胞和树突状细胞)向中枢神经系统迁移引起的多发性硬化症(MS)。据发现,整合素α4β1通过激活白细胞,参与细胞迁移过程[1,2]。
Firategrast与Natalizumab相比,半衰期短(2.5小时:4.5小时)。Firategrast抑制整合素与相关配体结合,包括血管细胞粘附蛋白1和黏膜地址素细胞黏附分子1。在中枢神经系统中,Firategrast治疗适度减少总淋巴细胞计数、淋巴细胞亚群计数和CD4/CD8比率。在外周血中,Firategrast治疗增加总淋巴细胞计数,所有淋巴细胞亚群计数以及早期外周CD34+造血干细胞计数[1,3]。
男性和女性在最大剂量(分别为1200 mg和900 mg)的Firategrast下均显示出良好的耐受性。在上述剂量下,Firategrast没有出现副作用,如PML或JC病毒复活。在I期临床试验中,给予Firategrast显著降低复发缓解型MS患者的新钆增强病变累积数目[1,3]。
参考文献:
[1] Grove R A, Shackelford S, Sopper S, et al. Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. European Journal of Neurology, 2013, 20(7): 1032-1042.
[2] Prat A, Stüve O. Firategrast—natalizumab in a pill. The Lancet Neurology, 2012, 11(2): 120-121.
[3] Miller D H, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 2012, 11(2): 131-139.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 499.5 |
Cas No. | 402567-16-2 |
Formula | C27H27F2NO6 |
Synonyms | SB 683699;SB683699;SB-683699 |
Solubility | ≥50 mg/mL in DMSO; insoluble in H2O; ≥90.8 mg/mL in EtOH with gentle warming |
Chemical Name | (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid |
SDF | Download SDF |
Canonical SMILES | CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)CC(C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Description | Firategrast是口服有效的整合素α4β1/α4β7拮抗剂。 | |||||
靶点 | α4β1/α4β7 integrin | |||||
IC50 |
质量控制和MSDS
- 批次: